Please login to the form below

Not currently logged in
Email:
Password:

Chiltern hires Roche’s Andrew Monaghan to head pharmacovigilance

He was global head of safety operations at pharma company

Roche's Andrew Monaghan has swapped pharma for clinical research by moving to Chiltern.

Monaghan, who was global head of safety operations at Roche, take on the role of director of global pharmacovigilance at the clinical research organisation Chiltern.

In this new role, he will lead Chiltern's pharmacovigilance team and expand the organisation's global pharmacovigilance offering.

“His strong leadership skills and extensive clinical experience will ensure our clients continue to receive customized and efficient safety solutions to meet their specific product and regulatory requirements, whether with investigational or postmarketed products,” said Dr Sharon Moore, executive VP, global medical and regulatory affairs.

Monaghan has served at Roche since 1997, when he joined as global head of PDO clinical management group.

Prior to this role he was director of regulatory affairs at Pfizer Global Research & Development.

25th July 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...
New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....

Infographics